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of MM patients have lost their immune competence and become aner-
gic to ZA-stimulation. The aim of this work was to identify strategies
to overcome myeloma-induced BM gδ T-cell immune dysfunction and
restore their anti-myeloma activity. Methods. gδ T cell immunopheno-
type: four color flow cytometry was used to determine the subset dis-
tribution of gδ T cells, the expression of the inhibitory receptors (PD-1
and BTLA) and of its ligands (PD-L1 and HVEM) in the tumor microen-
vironment. gδ T cell activation: MM BMMC were cultured for 7 days
in presence of IL-2 and ZA. On day 7, percentages and total counts of
viable gδ T cells were calculated with the trypan blue staining and flow
cytometry. BM gδ T cell proliferation and CD107 expression was also
evaluated in the presence of anti-PD1 blocking mAb. Myeloid-derived
suppressor cells (MDSC) and regulatory T cells (Tregs) inhibition: to
test the role of MDSC and Tregs in the anergy of MM BM gδ T cell,
BMMC were cultured for 7 days with IL2 and ZA in presence or absence
of functional inhibitors of these suppressor cells (sildenafil and 1-
methyl-tryptophan for MDSC;OX40L and anti-TGFb for Tregs). Results.
Our results point to a functional exhaustion of BM gδ T cells driven by
the local microenvironment as the main cause of immunoparesis.
Tumor cells and bystander cells in the BM microenvironment of MM
patients have an extremely accelerated Mevalonate pathway activity
leading to high concentrations of extra-cellular IPP in the tumor site. We
investigated the expression of programmed death-1 (PD-1) receptor, a
negative regulator of T cell activation and proliferation, on BM and PB
gδ T cells from MM patients and healthy donors. Interestingly, MM
BM gδ T cells showed the highest PD-1 expression, mainly in the sub-
set with the highest proliferative capacity (central memory). Moreover,
our data indicate that the late removal of Tregs and MDSC, negative
regulators locally recruited by myeloma cells, is not sufficient to rein-
state the immune competence of BM gδ T cell. Besides, our results
reveal that BM gδ T cells dysfunction is an early and long-lasting event
during the disease evolution. Conclusions.Our results evidence that neu-
tralization of the PD-1/PDL-1 axis partially reinstates BM gδ T cell reac-
tivity and improves their cytotoxic ability in MM patients.
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Introduction. Multiple myeloma (MM) is a heamotologic malignancy
characterized by proliferation of neoplastic plasma cells in the bone mar-
row (BM). Initially, myeloma cells strictly depend on BM, which supports
tumor progression through adhesion molecules and soluble mediators as
interleukin-6 (IL-6). Later, at the stage of plasma cell leukemia, MM cells
acquire mutations resulting in proliferation indipendent from environ-
mental factors such as IL-6. Recently, Notch signaling has been shown to
be upregulated during MM progression and to positively regulate cell
proliferation, drug resistance and BM infiltration. The aim of this study
is to evaluate if Notch signalling plays a role in the acquirement of IL-6
independence. Methods. The human MM cell lines CMA03, INA-6 and
XG1 were maintained in RPMI-1640 medium supplemented with IL-6
(respectivetly at 10, 2.5 and 1ng/ml). CMA03/06, OPM2 and U266 were
maintened in the same condition withouth IL-6. The murine fibroblasts
NIH3T3 were used as BMSC mimic and maintained in DMEM. Viable
cells were counted by trypan blue exclusion assay. Notch inhibition was
obtained by using the g-secretase inhibitor DAPT at 50mM, soluble
Jagged1 was used at 5mg/ml. qRT-PCR reactions were performed by
Maxima™ SYBR GreenqPCR Master Mix. Silencing of Jagged1 and 2
was obtained by transient expression of specific siRNAs (Select RNAiTM
siRNA system, Invitrogen). Results. The global expression analysis of the
MM model of IL-6 independence acquisistion represented by CMA03
and CMA03/06 cell line (Verdelli et al. Genes Chromosomes Cancer,
2014), indicated that Notch pathway activation may contribute to the IL-
6 independence in MM by inducing proliferative signals. Accordingly,
we showed here that the activation of Notch signaling, induced by stim-
ulation with soluble Jagged1 ligand, partially rescued IL-6 dependency in
XG1 cells. Otherwise, Notch signaling inhibition obtained with DAPT in
three different IL-6-indipendent MM cell lines (CMA03/06, OPM2 and
U266) resulted in a significant decrease of cell growth which could be
reverted by IL-6. This confirms that Notch and IL-6 are complementary
in activating MM cell proliferation. Of note, Notch withdrawal induced
by Jagged1/2 silencing, decreased IL-6 expression in OPM2 and U266
cell lines. This suggests that Notch-directed IL-6 regulation might have a
biological significance in those MM cell lines which express high IL-6 lev-
els. More frequently, BM stromal cells represent the main source of IL-6
for those MM cells which do not display an autonomous production.
Results from co-culture systems indicate that surface Jagged expressed on
MM cell lines induced Notch-directed IL-6 production in stromal cells.
This effect was reverted by silencing Jagged1/2 in MM cells. Conclusions.
These results suggest that Notch pathway activation may contribute to
the transition from IL-6-dependent to IL-6-independent cell growth, and
that its inhibition may result in decreased cell proliferation.
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